Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
about
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivoAnalysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomicsTherapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinomaThymic neoplasm: a rare disease with a complex clinical presentationA novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells.Oncogene mutational profile in nasopharyngeal carcinoma.MiRNA-125a-5p: a regulator and predictor of gefitinib's effect on nasopharyngeal carcinoma.Novel systemic therapeutic for nasopharyngeal carcinoma.Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells.Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
P2860
Q34353826-D62A3BF0-B164-4636-A5F5-D346F9F93113Q35122077-ECB55200-4A00-48E6-A982-AF0D78891E55Q35505126-D3499689-40B4-49F2-8B20-4A1EDECA27FCQ36166739-D2A05513-83A0-45EE-82C1-7FA79BFF74E3Q36317627-CF366AFB-2BB1-4FCA-9FFF-6BD64A8AE899Q36753888-509FD4A2-FAD5-449D-9CF1-48ED936B3B41Q37327734-6FF0F6E1-5318-4D83-A58A-EB065DCD3838Q37350214-6026689F-4F6B-465D-8D04-E3B7C9498BD4Q37660226-C5729551-E453-45B3-8CD4-7C98E431461CQ37681498-1889A00C-7430-49F0-A867-85AA667E1C86Q37982126-F0778941-BA07-447D-8C09-37891965144CQ39105272-12BCB9B1-56C1-45BA-9B05-1DFFFDD552EFQ41479561-9F49DE0D-F649-4396-8218-05C179B066CEQ54112985-8DB9ECF1-D64A-4369-8EC9-EECC05DF59D1
P2860
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Preclinical activity of gefiti ...... nes and biomarkers of response
@en
Preclinical activity of gefiti ...... es and biomarkers of response.
@nl
type
label
Preclinical activity of gefiti ...... nes and biomarkers of response
@en
Preclinical activity of gefiti ...... es and biomarkers of response.
@nl
prefLabel
Preclinical activity of gefiti ...... nes and biomarkers of response
@en
Preclinical activity of gefiti ...... es and biomarkers of response.
@nl
P2093
P2860
P1476
Preclinical activity of gefiti ...... nes and biomarkers of response
@en
P2093
Anthony T C Chan
Brigette B Y Ma
Elaine Wong
Fan Fong Poon
Honglin Chen
Kwok Wai Lo
Margaret Heung Ling Ng
S C Cesar Wong
P2860
P2888
P304
P356
10.1007/S10637-009-9316-7
P577
2009-09-16T00:00:00Z